Institutional members access full text with Ovid®

Share this article on:

Pulmonary Complications of Novel Antineoplastic Agents for Hematologic Malignancies

Vahid, Bobbak MD; Marik, Paul E. MD, FCCP

Clinical Pulmonary Medicine: March 2008 - Volume 15 - Issue 2 - pp 71-80
doi: 10.1097/CPM.0b013e3181671a2d
Interstitial, Inflammatory, and Occupational Lung Disease

Pulmonary complications in patients with hematologic malignancies is commonly encountered by clinicians. Some of these complications are believed to be related to direct toxicity of the drug itself. Novel antineoplastic agents with activity against hematologic malignancies are constantly being introduced into practice and clinical trials. This article reviews the pulmonary complications of these novel antineoplastic agents. Interstitial pneumonitis, eosinophilic pneumonia, noncardiogenic pulmonary edema, acute respiratory distress syndrome, pleural disease, and thromboembolic disease associated with individual antineoplastic agents are discussed. Clinical presentations, radiographic findings, pathology, pathogenesis, and management are also reviewed.

Pulmonary involvement in patients with hematologic malignancies is commonly encountered by clinicians. Pulmonary involvement may range from mild cough and dyspnea to extensive pulmonary infiltrates and respiratory failure. Novel antineoplastic agents with activity against hematologic malignancies are constantly being introduced into practice and clinical trials. Pulmonary toxicities of individual antineoplastic agents are discussed.

From the Department of Pulmonary and Critical Care Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Address correspondence to: Bobbak Vahid, MD, 834 Walnut Street Suite 650, Philadelphia, PA 19107. E-mail: bobbak_vahid@yahoo.com.

© 2008 Lippincott Williams & Wilkins, Inc.